20 completed, 7 recruiting, 5 active not recruiting, 1 not yet recruiting. 18 Phase 3, 12 Phase 1, 3 Phase 2.
By phase and status
Follow cagrilintide: new trials by email Literature Review of cagrilintide trials Research Report on cagrilintide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity CagriSema, Semaglutide, Cagrilintide - Hypertension, Obesity | Phase 3 | Not yet recruiting | 1408 | 2026-11-11 | 2026-11-05 |
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight Cagrilintide, Placebo cagrilintide, Placebo semaglutide - Overweight, Obesity | Phase 3 | Recruiting | 285 | 2026-08-04 | 2026-09-04 |
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events Cagrilintide, Placebo (matched to Cagrilintide) - Obesity, Overweight | Phase 1 | Recruiting | 114 | 2026-05-29 | 2026-10-19 |
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity Cagrilintide, Placebo Cagrilintide - Overweight, Obesity | Phase 1 | Recruiting | 120 | 2026-04-30 | 2026-05-15 |
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) Cagrilintide, Semaglutide, Placebo cagrilintide - Obesity | Phase 1 | Recruiting | 100 | 2026-04-10 | 2026-05-07 |
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese Glucose-dependent Insulinotropic Polypeptide (GIP), Cagrilintide, Placebo GIP - Overweight, Obese | Phase 1 | Recruiting | 100 | 2026-02-09 | 2026-04-13 |
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight Cagrilintide, Semaglutide, Placebo cagrilintide - Overweight, Obesity | Phase 3 | Recruiting | 460 | 2026-01-08 | 2026-09-30 |
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide Cagrilintide, Placebo - Obesity, Overweight | Phase 3 | Active not recruiting | 300 | 2025-11-05 | 2026-08-06 |
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide Cagrilintide, Placebo (matched to Cagrilintide) - Overweight, Obesity | Phase 3 | Active not recruiting | 330 | 2025-11-05 | 2026-11-16 |
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism Cagrilintide, Semaglutide, Placebo cagrilintide - Obesity | Phase 1 | Recruiting | 144 | 2025-06-12 | 2026-09-10 |
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity Cagrilintide, Semaglutide, Placebo cagrilintide - Obesity | Phase 3 | Active not recruiting | 400 | 2025-02-10 | 2026-01-20 |
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both Cagrilintide, Semaglutide, Tirzepatide - Diabetes Mellitus, Type 2 | Phase 3 | Completed | 1023 | 2024-11-05 | 2026-10-19 |
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight Cagrilintide, Semaglutide, Placebo - Obesity | Phase 3 | Completed | 300 | 2024-06-24 | 2026-05-05 |
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease NNC0194-0499, Semaglutide, NNC0194-0499 placebo - Alcohol-related Liver Disease | Phase 2 | Completed | 270 | 2024-05-20 | 2026-03-12 |
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes Semaglutide, Cagrilintide, Placebo semaglutide - Diabetes Mellitus, Type 2 | Phase 1 | Completed | 158 | 2024-05-06 | 2026-02-27 |
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo Cagrilintide, Semaglutide, Placebo - Chronic Kidney Disease, Type 2 Diabetes | Phase 2 | Completed | 626 | 2024-04-01 | 2026-09-24 |
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin Cagrilintide, Semaglutide, Placebo - Type 2 Diabetes | Phase 3 | Completed | 274 | 2024-03-26 | 2026-09-09 |
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise Cagrilintide, Semaglutide, Placebo - Type 2 Diabetes | Phase 3 | Completed | 189 | 2024-03-19 | 2026-09-30 |
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight Cagrilintide, Semaglutide, Atorvastatin - Obesity | Phase 1 | Completed | 34 | 2024-02-27 | 2026-05-19 |
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight Cagrilintide, Semaglutide, Placebo - Obesity | Phase 1 | Completed | 62 | 2024-02-23 | 2026-01-08 |
Showing 20 of 33. Sign in to see all of them.
Conditions studied
Obesity (23) · Overweight (12) · Diabetes Mellitus, Type 2 (10) · Cardiovascular Diseases (1) · Hypertension (1) · Renal Insufficiency, Chronic (1)
Sponsors
Novo Nordisk A/S (33)
Countries
United States (20) · Canada (15) · Germany (15) · Poland (11) · United Kingdom (11) · Denmark (10) · Argentina (9) · Australia (9) · Hungary (9) · Japan (9) · India (8) · Italy (8) · Spain (8) · Serbia (7) · Bulgaria (6)
Results publications
PMID 39279639, PMID 40544432, PMID 40544433, PMID 41328546, PMID 42009015, PMID 42228334, PMID 42251856, PMID 42251859, PMID 42251860, PMID 42838477
NIH funding
2023 (8), 2025 (3)